Issue 16 march 2020 Special Report 5 year Special Edition

Numéro 16 - 5 year Special Edition
Download for free

Bäckhed in 20041 and later Gordon in 20062 revealed the connection between the gut microbiota and obesity. In 2007, Amar and Cani3 demonstrated a causal link between the translocation of bacterial fragments in tissues and diabetes. Since these first publications, subsequent research has described the diversity of the microbiotas we host and confirmed the presence of microbiotas in our tissues, and the role of bacterial translocation on our health is now better understood. In the field of cardiovascular and metabolic diseases, the role of intestinal immunity in interaction with the gut microbiota has been revealed for both diabetes and hypertension, paving the way for an aetiological treatment for what Reaven, for want of a better name, called syndrome X4 in 1998. In the field of cancer, the role of the gut microbiota in the tolerance and efficacy of immunotherapy has been reported, opening up new possibilities for precision medicine5. The role of tumour tissue dysbiosis in the prognosis of cancers like pancreatic cancer has also been established6. The physiopathological mechanism of this relationship has now been identified, paving the way for innovative therapies targeting the interaction between the host’s immunity and the bacteria present in the tumour. In a few short years, we have therefore expanded our very narrow and sterile view of the human body to embrace a new paradigm where the dialogue established from birth between our microbiota and our cells has a major influence on our health. Understanding and modulating this dialogue to our advantage is therefore set to be a major challenge for scientific research in the decade to come.

Good reading and good navigation!


1. Bäckhed F, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad
Sci USA. 2004;101:15718-23
2. Turnbaugh PJ, et al. An obesity-associated gut microbiota with increased capacity for energy harvest. Nature.
3. Cani PD, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-72.
4. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
5. Routy B, et al. Gut microbiota influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Science. 2018;359:91-7.
6. Riquelme E, et al. Tumor Microbiota Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell.

Read more

Table of contents

Special Report

  • Gut microbiota analysis: the future of personalised medicine?Philippe Gérard
  • Gut microbiota and gastrointestinal disorders: from prevention to treatmentStanislas Bruley des Varannes
  • The microbiota: a link between cardiovascular and metabolic diseasesJacques Amar
  • Microbiota and gynaecology: an increasingly vast horizon with as yet undefined solutionsJean-Marc Bohbot
  • The emergence of the newborn gut microbiota: the lessons of the last five yearsAlexis Mosca
  • Microbiota and immune dysfunction diseases: causes or consequences?Cyrille Hoarau
  • Lung microbiota, out of the shadowsGeneviève Héry-Arnaud
  • Microbiota and neuroscience: the importance of the gut-brain axisPatrick Vermersch
  • Taxonomy of the microbiota: the impact of innovative technologiesBruno Pot

The Microbiota Chronicle

  • Pull-out poster: 15 Revues des Microbiotes in summary; Gloss ary

In Brief

  • Five years of Zoom in summary

Microbiota News

  • Interesting abstracts



LoginFor free access to all issues & a notification upon publication of each new issue

Forgotten password ?

Password requestHave you forgotten your password? Enter your email address and we will send you a message with the password reset procedure.


Not yet registered ?

Create an account free of charge

Create an accountFor free access to all issues & a notification upon publication of each new issue

If you wish to subscribe to the paper version of La Revue des Microbiotes and have it delivered to your door, please contact our Subscription Department:

  • ?
  • As a result, I accept that my email address will be forwarded to the company PILEJE (SAS – French simplified joint stock company – with a capital of €1,190,400,00 - registered at the companies register in Paris under the number 950 450 452 – 37, Quai de Grenelle, 75738 PARIS Cedex 15)

The information included in this form is intended for the company LARENA, responsible for processing, for the purposes of processing your request and managing our relationship.

In accordance with French law no. 78-17 of 6 January 1978, as amended, and European Regulation 2016/679 of 27 April 2016, you have the right to access, correct, restrict or delete data concerning you or exercise your right to opposition or right to portability. You can exercise these rights by making a request in writing, accompanied by proof of identity, to LARENA – DPO – 1 ZI du Taillis – Champtoceaux – 49270 Orée d’Anjou, France or to

For more information about the management of your personal data

*These fields are required to process your request. Without this information, we will be unable to process your request .

Already registered


Sample copyAccess the first issue free of charge without creating an account

Numéro 1 - Microorganisms and mankind
5 years of La Revue des Microbiotes !Watch the video